GLP-1

News

Lawmaker asks FTC to probe Novo/Catalent deal

US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently operate

Digital

Advancing Precision Care For All

Precision medicine is oft spoken about these days, as it is finally addressing the elephant in the room: one size – or, more appropriately, one dose – does not fit all.

R&D

Weight loss gold rush: Developers vie for next blockbuster t...

Weight loss treatments are rapidly becoming a focal point for pharma R&D, driven by the commercial success of Eli Lilly and Novo Nordisk’s therapies.

News

Mounjaro and Zepbound shortages over, declares FDA

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in

News

Noom offers cut-price compounded GLP-1 drug for obesity

Digital health company Noom has launched a compound pharmacy-made version of Novo Nordisk's obesity drug semaglutide to make the drug more accessible to consumers in the US.

News

Study backs role of Novo Nordisk obesity drug in children

A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).

Lawmaker asks FTC to probe Novo/Catalent deal

Advancing Precision Care For All

Weight loss gold rush: Developers vie for next blockbuster t...

Mounjaro and Zepbound shortages over, declares FDA

Noom offers cut-price compounded GLP-1 drug for obesity

Study backs role of Novo Nordisk obesity drug in children

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

GLP-1

Editor's Picks